Contact

All Stories

  1. Two randomized controlled Phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency

    Article • European Respiratory Journal, September 2025, European Respiratory Society (ERS)

    Professor Kenneth R Chapman

  2. Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline

    Article • CHEST Journal, April 2025, Elsevier

    Professor Kenneth R Chapman

  3. Clinically Important Deterioration (CID) in a mild-moderate COPD population

    Article • ERJ Open Research, March 2025, European Respiratory Society (ERS)

    Professor Kenneth R Chapman

  4. Alpha-1-antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society meta-analysis and clinical practice guideline

    Article • Canadian Journal of Respiratory Critical Care and Sleep Medicine, March 2025, Taylor & Francis

    Professor Kenneth R Chapman

  5. Long-Term Efficacy of Dupilumab in Moderate-to-Severe Asthma Phenotyped by Blood Eosinophils and Exhaled Nitric Oxide

    Article • CHEST Pulmonary, March 2025, Elsevier

    Professor Kenneth R Chapman

  6. Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study

    Article • Respiratory Medicine, October 2023, Elsevier

    Professor Kenneth R Chapman

  7. Triple inhaled therapy for asthma in Canada

    Article • Canadian Journal of Respiratory Critical Care and Sleep Medicine, August 2023, Taylor & Francis

    Professor Kenneth R Chapman

  8. The effect of exacerbations on lung density in α1-antitrypsin deficiency

    Article • ERJ Open Research, December 2022, European Respiratory Society (ERS)

    Professor Kenneth R Chapman

  9. Association of Obstructive Apnea with Thoracic Fluid Shift and Small Airways Narrowing in Asthma During Sleep

    Article • Nature and Science of Sleep, May 2022, Taylor & Francis

    Professor Kenneth R Chapman

  10. Primary Care Severe Asthma Registry and Education Project (PCSAR-EDU): Phase 1 – an e-Delphi for registry definitions and indices of clinician behaviour

    Article • BMJ Open, March 2022, BMJ

    Professor Kenneth R Chapman

  11. Long-Term Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarker Patients With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA TRAVERSE

    Article • Journal of Allergy and Clinical Immunology, February 2022, Elsevier

    Professor Kenneth R Chapman

  12. If All That You Have Is a Hammer…: Can We Phenotype Our Patients with Chronic Obstructive Pulmonary Disease?

    Article • American Review of Respiratory Disease, February 2022, American Thoracic Society

    Professor Kenneth R Chapman

  13. When less is more in asthma management

    Article • The Journal of Allergy and Clinical Immunology In Practice, December 2021, Elsevier

    Professor Kenneth R Chapman

  14. A tail of two diagnoses: Supporting patients with both COPD and Cardiovascular risks

    Article • October 2021, Springer Science + Business Media

    Professor Kenneth R Chapman, Professor Deepak L Bhatt

  15. A structured review of the ASCENT Study for COPD

    Article • Advances in Therapy, September 2021, Springer Science + Business Media

    Professor Kenneth R Chapman, Professor Deepak L Bhatt

  16. Efficacy of MF/IND/GLY to reduce asthma exacerbation

    Article • September 2021, European Respiratory Society (ERS)

    Professor Kenneth R Chapman

  17. Just as the Twig Is Bent, the Tree’s Inclined

    Article • Annals of the American Thoracic Society, September 2021, American Thoracic Society

    Professor Kenneth R Chapman

  18. Pooled data from PALLADIUM and IRIDIUM studies- The impact of Breezhaler® once daily

    Article • BMJ Open Respiratory Research, August 2021, BMJ

    Professor Kenneth R Chapman

  19. The cause of COPD is not always smoking history.

    Article • American Review of Respiratory Disease, June 2021, American Thoracic Society

    Professor Kenneth R Chapman

  20. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO

    Article • International Journal of Chronic Obstructive Pulmonary Disease, June 2021, Taylor & Francis

    Professor Kenneth R Chapman

  21. The experience of asthma from the patient and physicians

    Article • Respiratory Medicine, June 2021, Elsevier

    Professor Kenneth R Chapman

  22. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

    Article • May 2021, Springer Science + Business Media

    Professor Kenneth R Chapman

  23. The survey for Asthma Patients’ and Physicians’ Perspectives on the Burden and Management of Asthma

    Article • May 2021, American Thoracic Society

    Professor Kenneth R Chapman

  24. The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2021, Taylor & Francis

    Professor Kenneth R Chapman

  25. The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, February 2021, Taylor & Francis

    Professor Kenneth R Chapman

  26. A review of the past, present and future for Alpha-1 Antitrypsin Deficiency

    Article • American Journal of Respiratory Cell and Molecular Biology, October 2020, American Thoracic Society

    Professor Kenneth R Chapman

  27. Reducing the hidden burden of severe asthma: recognition and referrals from primary practice

    Article • Journal of Asthma, May 2020, Taylor & Francis

    Professor Kenneth R Chapman

  28. Working smarter to improve asthma care

    Article • May 2020, American Thoracic Society

    Professor Kenneth R Chapman

  29. Status of Severe Asthma Management in Canada

    Article • Canadian Journal of Respiratory Critical Care and Sleep Medicine, December 2019, Taylor & Francis

    Professor Kenneth R Chapman, Erika Penz

  30. Treatment of Asthma with Breezhaler

    Article • September 2019, European Respiratory Society (ERS)

    Kenneth Chapman, Professor Kenneth R Chapman

  31. Long term impacts of tobacco and marijuana smoking on lung function

    Article • European Respiratory Journal, September 2019, European Respiratory Society (ERS)

    wan tan, Professor Kenneth R Chapman

  32. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD

    Article • European Respiratory Journal, August 2019, European Respiratory Society (ERS)

    Professor Kenneth R Chapman

  33. Improving maintenance treatment for COPD patients

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2019, Dove Medical Press

    Professor Kenneth R Chapman, driss rochdi, Andrew McIvor

  34. COPD exacerbation rates with IND/GLY

    Article • International Journal of Chronic Obstructive Pulmonary Disease, April 2018, Dove Medical Press

    Claus Vogelmeier, Professor Kenneth R Chapman, Dr. Konstantinos Kostikas, Jørgen Vestbo

  35. An update on Alpha 1 antitrypsin deficiency

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2018, Dove Medical Press

    Professor Kenneth R Chapman, Rembert Koczulla, Noel G McElvaney

  36. Self-Management and Clinical Decision Support for Patients With Complex Chronic Conditions Through the Use of Smartphone-Based Telemonitoring: Randomized Controlled Trial Protocol

    Article • JMIR Research Protocols, November 2017, JMIR Publications Inc.

    Professor Kenneth R Chapman

  37. A review of COPD from the 2015 European Respiratory Society Congress

    Article • Respiratory Medicine, March 2016, Elsevier

    Professor Kenneth R Chapman

  38. Safety of Breezhaler® device

    Article • International Journal of Chronic Obstructive Pulmonary Disease, August 2015, Dove Medical Press

    Professor Kenneth R Chapman, Pankaj Goyal

  39. The prevalence of asthma and atopy in schoolchildren from Porto Alegre, Brazil, has plateaued

    Article • Respiratory Medicine, March 2015, Elsevier

    Professor Kenneth R Chapman

  40. Clinical Relevance of Fixed Ratio vs Lower Limit of Normal of FEV1/FVC in COPD: Patient-Reported Outcomes From the CanCOLD Cohort

    Article • The Annals of Family Medicine, January 2015, Annals of Family Medicine

    Professor Kenneth R Chapman

  41. Exacerbations in non-COPD patients: truth or myth—authors’ response

    Article • Thorax, July 2014, BMJ

    Professor Kenneth R Chapman

  42. Quality Assurance of Spirometry in a Population-Based Study –Predictors of Good Outcome in Spirometry Testing

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, March 2014, Taylor & Francis

    Professor Kenneth R Chapman

  43. Comparing the standard COPD drug treatment to a new drug: Tiotropium VS. Glycopyrronium

    Article • BMC Pulmonary Medicine, January 2014, Springer Science + Business Media

    Professor Kenneth R Chapman

  44. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries

    Article • Journal of Asthma, November 2013, Taylor & Francis

    Professor Kenneth R Chapman

  45. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study

    Article • Respiratory Medicine, October 2013, Elsevier

    Professor Kenneth R Chapman

  46. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

    Article • The Lancet Respiratory Medicine, September 2013, Elsevier

    Professor Peter Anthony Frith, Professor Kenneth R Chapman

  47. Do We Know the Minimal Clinically Important Difference (MCID) for COPD Exacerbations?

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, March 2013, Taylor & Francis

    Professor Kenneth R Chapman

  48. Bronchodilator Responsiveness and Reported Respiratory Symptoms in an Adult Population

    Article • PLOS One, March 2013, PLOS

    Professor Kenneth R Chapman

  49. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach

    Article • Orphanet Journal of Rare Diseases, January 2013, Springer Science + Business Media

    Professor Kenneth R Chapman

  50. Asthma controller delay and recurrence risk after an emergency department visit or hospitalization

    Article • Respiratory Medicine, December 2012, Elsevier

    Professor Kenneth R Chapman

  51. What Do We Know about Asthma Triggers? A Review of the Literature

    Article • Journal of Asthma, November 2012, Taylor & Francis

    Professor Kenneth R Chapman

  52. A Step Forward in COPD Management

    Article • CHEST Journal, November 2012, Elsevier

    Professor Kenneth R Chapman

  53. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease

    Article • Canadian Medical Association Journal, July 2012, Canadian Medical Association (CMA)

    Professor Kenneth R Chapman

  54. The Association Between Chronic Exposure to Traffic-Related Air Pollution and Ischemic Heart Disease

    Article • Journal of Toxicology and Environmental Health Part A, April 2012, Taylor & Francis

    Professor Kenneth R Chapman

  55. Profile of eicosanoids in breath condensate in asthma and COPD

    Article • Journal of Breath Research, March 2012, Institute of Physics Publishing

    Professor Kenneth R Chapman

  56. Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, March 2012, Taylor & Francis

    Professor Kenneth R Chapman

  57. Improved outcomes and adherence with novel COPD treatment: Indacaterol

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2012, Taylor & Francis

    Professor Kenneth R Chapman

  58. Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor

    Article • European Respiratory Journal, January 2012, European Respiratory Society (ERS)

    Professor Kenneth R Chapman

  59. The SMART treatment for asthma isn't as smart as it seems

    Article • Clinical & Experimental Allergy, January 2012, Wiley

    Professor Kenneth R Chapman

  60. Can age and sex explain the variation in COPD rates across large urban cities? A population study in Canada

    Article • The International Journal of Tuberculosis and Lung Disease, December 2011, International Union Against Tuberculosis and Lung Disease

    Professor Kenneth R Chapman

  61. Long-term Safety and Efficacy of Indacaterol, a Long-Acting β 2 -Agonist, in Subjects With COPD

    Article • CHEST Journal, July 2011, Elsevier

    Professor Kenneth R Chapman

  62. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, June 2011, Taylor & Francis

    Professor Kenneth R Chapman

  63. Nontuberculous Mycobacterial Infection as a Cause of Difficult-to-Control Asthma

    Article • CHEST Journal, January 2011, Elsevier

    Professor Kenneth R Chapman

  64. Infection with Mycoplasma pneumoniae is not related to asthma control, asthma severity, and location of airway obstruction

    Article • International Journal of General Medicine, December 2010, Taylor & Francis

    Kamyar Ghabili, Professor Reza Ghotaslou, Professor Kenneth R Chapman

  65. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study

    Article • BMC Clinical Pharmacology, September 2010, Springer Science + Business Media

    Professor Kenneth R Chapman

  66. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal

    Article • Thorax, June 2010, BMJ

    Professor Kenneth R Chapman

  67. Dynamic Airway Evaluation with Volume CT: Initial Experience

    Article • Canadian Association of Radiologists Journal, April 2010, SAGE Publications

    Professor Kenneth R Chapman

  68. Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma

    Article • Respiratory Medicine, April 2010, Elsevier

    Professor Kenneth R Chapman

  69. SMART isn't

    Article • Journal of Allergy and Clinical Immunology, March 2010, Elsevier

    Professor Kenneth R Chapman

  70. Asthma that is unresponsive to usual care

    Article • Canadian Medical Association Journal, October 2009, Canadian Medical Association (CMA)

    Professor Kenneth R Chapman